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Background: Lauren-classification and human epidermal growth factor receptor 2 (HER2) status are two important
pathological features of gastric cancer patients. The prognostic value of HER2 in gastric cancer remains
controversial. Intestinal type gastric cancer has better prognosis and higher HER2 positive proportion. What is the
interaction between these two factors? We hypothesized that a combination of Lauren-classification and human
epidermal growth factor receptor 2 (HER2) status (L-H status) might be more meaningful than either factor alone.
Methods: We collected 838 gastric cancer patients at all stages who had received treatment in our cancer center.
This study was registered in the website of ClinicalTrials.Gov, with the number NCT01927146. We divided the
patients into six groups according to their L-H status: Group A, HER2 negative and intestinal type; Group B, HER2
positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type;
Group E, HER2 negative and mixed type; and Group F, HER2 positive and mixed type.
Results: Diffuse type and intestinal type accounted for 51.0% and 33.9%, respectively. The proportion of HER2
positive patients was 11.2%, 25.4%, 2.1% and 10.2% in the whole patient group, intestinal, diffuse and mixed type,
respectively. Median overall survival was 34.0 months, 25.3 months, 27.6 months, 19.2 months, 25.9 months and
26.4 months in the six groups patients, P = 0.053. There was a significant difference in survival among the first four
groups (P < 0.001). HER2 was an independent prognostic factor in the intestinal type and in stage I + II patients,
but not in the diffuse type or stage III + IV patients. L-H status was an independent prognostic factor in patients at
all stages. For the diffuse and intestinal types, the multivariate analysis showed that HER2 was not an independent
prognostic factor, while Lauren classification and L-H status were. Moreover, L-H status was a better prognostic
factor than the Lauren classification.
Conclusions: L-H status is a prognostic factor in diffuse and intestinal type patients, but not in the mixed type.
Patients with HER2 negative and intestinal type had the best survival, while patients with HER2 positive status and
diffuse type had the worst survival.
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Gastric cancer is the second most common cause of
cancer-related death worldwide [1]. The incidence of gas-
tric carcinoma varies significantly from one part of the
world to another and it is particularly common in Eastern
Asia, especially in China [2]. Amplification, overexpression
or both, of human epidermal growth factor receptor-2
(HER2, also known as ERBB2), a transmembrane receptor
tyrosine kinase, is present in around 6.1–23.0% of gastric
cancers [3-5]. In breast cancer, amplification and overex-
pression of the HER2 gene are associated with poor out-
comes, higher mortality, higher recurrence and metastasis
[6-8]. However, the prognostic value of HER2 status in
gastric cancer remains controversial. Some studies showed
that HER2-positive patients had a favorable survival [9-11],
while other studies revealed no relationship between HER2
status and survival [4,12-14]. The majority of the publi-
cations showed that a HER2-postive status, measured by
immunohistochemistry (IHC) or fluorescence in situ hy-
bridization (FISH), was associated with poor survival and/
or clinicopathological characteristics, such as serosal inva-
sion, lymph node metastases, disease stage, or distant me-
tastases [11,15,16].
Although the Lauren classification system dates back to
1965, it is still widely accepted and employed by patholo-
gists and physicians today. According to the Lauren classi-
fication, gastric adenocarcinomas can be divided into
diffuse, intestinal and mixed type [17]. Cohesive cells that
form gland-like structures characterize the intestinal type.
For the diffuse type, tumor cells lack cell-to-cell interac-
tions and infiltrate the stroma as single cells or small sub-
groups, leading to a population of non-cohesive, scattered
tumor cells [17]. The intestinal-type is more frequent in
males and in elderly patients, while the diffuse-type occurs
more frequently in women and young patients [18]. Intes-
tinal type patients have better outcomes than patients with
diffuse-type tumors [8,19-21]. However, HER2 positivity is
more common in intestinal-type gastric cancer [15]. The
higher rate of HER2 positivity and better survival in the
intestinal type is controversial. We hypothesized that the
combination of the Lauren classification and HER2 status
(L-H status) might be more helpful than either factor
alone. In this study, we explored the relationship between
Lauren classification and HER2 status; moreover, we also
analyzed the prognostic value of L-H status.
Methods
Patient collection
From January 1996 to December 2006, we collected clinical
information retrospectively from gastric cancer patients
who received treatment in our cancer center. Patients
included in the study met the following criteria: (1) histo-
logically confirmed gastric adenocarcinoma patients that
underwent gastrectomy; (2) adequate paraffin-embeddedtumor tissue sample for pathological and HER2 status
analysis; and (3) complete medical records with regular
survival follow-up data. Overall survival (OS) data was
present. The exclusion criteria were: (1) age <18 years old;
and (2) other malignancy within the last 5 years, except
carcinoma in situ of the cervix, or basal cell carcinoma.
All patients were categorized according to the 7th
American Joint Committee on Cancer (AJCC) Tumor-
Node-Metastasis (TNM) stage.
Lauren classification
Assignment of histological type was based on the Lauren
criteria. The intestinal type was described as a tumor with
glandular architecture, resembling colonic carcinoma. The
diffuse type was described as a tumor composed of solitary
or small clusters of cells, and lacking glandular structures.
The mixed type was described as the combination of these
two features. Two pathologists reviewed the original diag-
nostic slides to make a diagnosis of Lauren classification.
HER2 evaluation
Immunohistochemistry (IHC)
For all patients, HER2 expression was detected by IHC.
IHC staining was carried out using an anti-HER-2/NEU
(4B5) antibody (Ventana Medical Systems, Inc. Tucson,
AZ, USA) as the primary antibody against HER2 on a
Ventana Benchmark XT automatic staining system, ac-
cording to the manufacturer’s instructions. The amended
HER2 IHC scoring system for gastric cancer proposed
by Hoffmann et al. was used as the criteria for scoring
the stained slides [22].
Fluorescence in situ hybridization (FISH)
HER2 amplification levels were measured when the re-
sult of IHC was 2+. The PathVysion®HER2 DNA Probe
kit (LSI®HER2/neu Spectrum Orange™/chromosome 7
centromere probe (CEP) ®17 Spectrum Green) was used
to perform FISH analysis, according to the manufac-
turer’s protocol. A positive result from FISH was defined
as a HER2:CEP17 ratio ≥2.
Any case with IHC 3+ or IHC2+/FISH + was consid-
ered to be HER2-positive, while cases with IHC 0 or
IHC 1+ or IHC 2+/FISH −were considered as HER2-
negative, according to criteria of the European Medi-
cines Agency.
L-H status
We divided the patients into six groups according to
their Lauren classification and HER2 status (L-H Status):
Group A, HER2 negative and intestinal type; Group B,
HER2 positive and intestinal type; Group C, HER2 nega-
tive and diffuse type; Group D, HER2 positive and dif-
fuse type; Group E, HER2 negative and mixed type; and
Group F, HER2 positive and mixed type.
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The Statistical Package of Social Sciences 13.0 software per-
formed all the statistical analyses. A P value <0.05 was con-
sidered statistically significant. The Kaplan-Meier method
was used to estimate OS. For patients who remained
alive, data were censored at the date of the last contact.
Kaplan-Meier analysis with log-rank testing was used for
univariate analysis. OS was defined as the duration be-
tween the date of diagnosis and the date of last contact.
Variables showing a trend for association with survival
(P <0.05) and variables that were known to have prognos-
tic value were selected for submission to a final multivari-
ate Cox proportional hazards model, while variables that
were highly associated with others were excluded from the
final multivariate model. The chi-square test was used to
compare the clinicopathological data.
We compared the -2log likelihood (which was the par-
ameter in the Cox regression) of two different models of
multivariate analysis: the smaller the value, the better the
model [23].
Ethics statement
All patients signed written informed consent for their in-
formation to be used for the study. The independent
ethics committees at the Cancer Center of Sun Yat-Sen
University approved the study. The study was undertaken
in accordance with the ethical standards of the World
Medical Association Declaration of Helsinki.
This study was registered in the website of Clinical-
Trials.Gov with a number of NCT01927146.
Results
Patient demographics
The median age of the 838 patients was 59 years (rang: 18
to 86 years); 554 were male and 284 were female. There
were 88 stage IV patients at the time of diagnosis who all
received gastrectomy to relieve the symptom of obstruc-
tion or bleeding. During follow-up, 91 patients developed
distant metastasis and 12 patients had local recurrence.
Until January 1, 2014, 77 patients had died from gastric
cancer.
Lauren classification
There were 51.0% (427/838) of patients with diffuse type
and 33.9% (284/838) patients with the intestinal type. The
remaining 127 (15.1%) patients belonged to the mixed type.
The relationship between clinicopathological features
and Lauren classification is showed in Table 1. Among the
patients who were younger than 60 years old, 269 (62.7%)
had the diffuse type, while for patients who were older
than 59 years old; only 158 (38.6%) patients had the diffuse
type. The ratio of males to females was significantly higher
in the intestinal-type than that in the diffuse-type (3.2 vs.1.3; P < 0.001). Patients in stages III and IV had a higher
percentage of diffuse type than those in the stages I and II.
HER2 status
The percentages of IHC negative, 1+, 2+ and 3+ were
51.2% (429/838), 25.5% (214/838), 15.4% (129/838) and
7.9% (66/838), respectively. For the IHC 2+ patients, 28
patients were diagnosed as FISH positive. Thus, the pro-
portion of patients positive for HER2 was 11.2% (94/838)
in the whole group of patients.
Among patients who were older than 60 years, there were
more HER2 positive patents than among those younger
than 59 years old. Stage IV patients had the highest propor-
tion of HER2 positive (14.8%). The relationship between
clinicopathological features and HER2 status is shown in
Table 1.
L-H status
The proportions of HER2 positive patients were 25.4%,
2.1% and 10.2% in the intestinal type, diffuse type and
mixed type, respectively (P < 0.001). The median OS (from
the time of diagnosis to the time of last contact) was
34.0 months, 25.3 months, 27.6 months, 19.2 months,
25.9 months and 26.4 months in the six groups of patients
(P = 0.053). Considering that the mixed type contained the
features of diffuse type and intestinal type, the difference
between diffuse and intestinal type could not be fully eval-
uated in the mixed type. In subsequent analyses we only
evaluated the value of L-H classification in the diffuse and
intestinal types. The number of patients in these four
groups was 212, 72, 418 and nine respectively. The median
survival was 34.0 months, 25.3 months, 27.6 months and
19.2 months (P < 0.001; Figure 1). For the stage IV patients
(including 88 concurrent metastasis and 91 metachronous
metastasis patients), if we calculated the survival from the
time of metastasis to the time of last contact, the median
overall survival was 13.7 months, 10.2 months, 10.8 months
and 7.9 months (P = 0.001).
The relationship between L-H status and clinicopatho-
logical features is shown in Table 2. From the table, we
could conclude that L-H status was a useful index.
Among the four L-H groups, the clinicopathological fea-
tures were quite different, except for the percentage of
adjuvant chemotherapy.
Survival analysis
Both univariate and multivariable analyses were used to
evaluate factors associated with OS. Factors of TNM stage
(P < 0.001), degree of differentiation (P = 0.015), Lauren
classification (P = 0.006), HER2 status (P = 0.033) and L-H
status (P = 0.003) were all significantly associated with OS
in the univariate analysis.
To further explore the prognostic value of HER2, we
analyzed the survival difference between HER2 positive
Table 1 Baseline characteristics
Lauren classification P# value HER2 status P* value
Diffuse(%) Intestinal(%) Mixed(%) Negative(%) Positive(%)
Sex <0.0
Male 242 (43.7) 216 (39.0) 96 (17.3) 01 486 (87.7) 68 (12.3) 0.176
Female 185 (64.7) 68 (23.9) 31 (10.9) 258 (90.8) 26 (9.2)
Age <0.001 <0.001
≤59 269 (62.7) 104 (24.2) 56 (13.1) 398 (92.8) 31 (7.2)
>59 158 (38.6) 180 (44.0) 71 (17.4) 346 (84.6) 63 (15.4)
Stage <0.001 0.406
I 68 (47.9) 60 (42.3) 14 (9.8) 131(92.3) 11 (7.7)
II 96 (41.7) 102 (44.3) 32 (13.9) 203 (88.3) 27 (11.7)
III 215 (56.9) 95 (25.1) 68 (18.0) 335 (88.6) 43 (11.4)
IV 48 (54.5) 27 (30.7) 13 (14.8) 75 (85.2) 13 (14.8)
Degree of differentiation <0.001 <0.001
Well + Moderate 0 (0) 262 (76.2) 82 (23.8) 270 (78.5) 74 (21.5)
Poor + signet ring cell 427 (86.4) 22 (4.5) 45 (9.1) 474 (96.0) 20 (4.0)
Location <0.001 <0.001
Proximal 110 (35.9) 146 (47.7) 50 (16.3) 251 (82.0) 55 (18.0)
Distal 276 (59.1) 128 (27.4) 63 (13.5) 436 (93.4) 31 (6.6)
Total stomach 41 (63.1) 10 (15.4) 14 (21.5) 57 (87.7) 8 (12.3)
Adjuvant chemotherapy
Yes 302 (51.4) 192 (32.7) 94 (15.9) 531 (90.3) 57 (9.7)
No 77 (47.5) 65 (40.1) 20 (12.4) 0.170 138 (85.2) 24 (14.8) 0.063
HER2: human epidermal growth factor receptor 2.
#P values of Lauren classification in different clinical features. *P values of HER 2 status in different clinical features.
Figure 1 The survival difference among different L-H status.
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Table 2 The relationship between different L-H status
and clinical features
Group A Group B Group C Group D P value
Sex
Male 163 54 235 6
Female 49 18 183 3 <0.001
Age
≤59 82 21 264 6
>59 130 51 154 3 <0.001
Stage
I 48 10 69 1
II 80 23 93 2
III 66 30 211 3
IV 18 9 45 3 <0.001
Degree of
differentiation
Well + Moderate 193 69 0 0
Poor + signet ring cell 19 3 418 9 <0.001
Location
Proximal 99 45 111 1
Distal 104 24 269 7
Total stomach 9 3 38 1 <0.001
Adjuvant
chemotherapy
Yes 144 48 297 5
No 50 15 76 1 0.505
Group A, HER2 negative and intestinal type; Group B, HER2 positive and
intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2
positive and diffuse type.
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type, respectively. We found that HER2 positivity was an
independent adverse prognostic factor in the intestinal
type (P < 0.001), but not in the diffuse type (P = 0.084;
Figure 2A, B).
We then analyzed the prognostic value of HER2 posi-
tivity in different stages. HER2 positivity was an inde-
pendent adverse prognostic factor in stage I and II
patients (P < 0.001), but not in stage III and IV patients
(P = 0.125; Figure 2C, D).
For the multivariable regression analysis, we first set
up a model (model A) that included age, gender, degree
of differentiation, TNM stage, Lauren classification and
HER2 status. Model A showed that age, degree of differ-
entiation, TNM stage and Lauren classification were in-
dependent factors for OS (P = 0.001, 0.017, <0.001 and
0.047, respectively, Table 3). HER2 status was not an in-
dependent prognostic factor (P = 0.285). The -2log likeli-
hood was 1663.155. We then set up another model
(model B), which was identical to the first one except
that the Lauren classification and HER2 status werereplaced by the L-H status. In model B, TNM stage and
L-H status were independent factors for OS (P = 0.028,
<0.001 and 0.006, respectively, Table 3). The -2log likeli-
hood was 1411.610.
We also analyzed the prognostic value of L-H status
in different stages. L-H status was an independent prog-
nostic factor in both early stage (I and II) patients (P <
0.001) and advanced stage (III and IV) patients (P = 0.036;
Figure 3A, B).Discussion
The prognostic value of HER2 status in gastric cancer
remains controversial. Some studies reported that HER2
positivity was an adverse prognostic factor, while some
found that it indicated better survival. Other studies
even considered that it had no relationship with survival.
Based on the Lauren classification, gastric cancers could
be divided into the diffuse type, intestinal type and
mixed type. The intestinal type has a better survival than
the diffuse type. However, intestinal type patients were
more likely to be HER2 than diffuse type patients. In our
study, HER2 was not an independent prognostic factor
for gastric cancer patients in the multivariate analysis.
When we separated the patients into diffuse and intes-
tinal types, we found that HER2 was an independent ad-
verse prognostic factor for the intestinal type. We also
analyzed the prognostic value of HER2 positivity in pa-
tients at different stages. HER2 positivity was an inde-
pendent prognostic factor for stage I and II patients, but
not in stage III and IV patients. This was different from
the result of Kataoka et al. [14]. They analyzed 213 Japanese
gastric cancer patients retrospectively and found that
the OS of HER2-negative and -positive patients was
not significantly different in the whole group patients.
However, in patients with stage III/IV, they found that
the OS was worse in HER2-positive patients (P = 0.0149)
[14]. In the 2012 European Society for Medical Oncol-
ogy (ESMO) conference, a multicenter study conducted
by Kurokawa et al. showed that HER2 positivity was an
independent prognostic factor in stage I and II patients,
but not in stage III and IV patients [24]. This was con-
sistent with our results. These were all retrospective
analyses. Therefore, prospective studies are required to
explore the prognostic value of HER2 in early stage gas-
tric cancer patients.
Based on the analysis above, we hypothesized that when
we discussed the prognostic value of HER2 positive, there
were other factors that should be into consideration, such
as the TNM stage and the Lauren classification.
HER2 positivity was much more common in the prox-
imal, intestinal type and stage IV gastric cancer patients.
Male, older patients and proximal gastric cancer patients
had a higher percentage of intestinal type. These basic
Figure 2 Kaplan–Meier curves of HER2-positive and -negative patients for overall survival in (A), intestinal type (B), diffuse type (C),
TNM stage I/II and (D) TNM stage III/IV.
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ous studies [4,15,16,18-21].
In the 2014, at the American Society of Clinical Oncology
(ASCO) annual meeting, both HER2 positivity and the
Lauren classification were considered as the most importantTable 3 The multivariable analysis of overall survival in gastr
Model A




Degree of differentiation 0.505 0.288-0.886
Lauren classfication 1.440 1.004-2.066
HER2 status 0.669 0.320-1.398
L-H status – –
Abbreviations: CI confidence interval, HER2 human epidermal growth factor recepto
Model A includes the factors of Lauren classification and HER2 status; Model B incluprogresses in gastric cancer in the last 50 years. These were
two important pathological features of gastric cancer. In the
present study, we combined these two factors together and
proposed the concept of L-H status. Since mixed type was
not a pure group, L-H status is not a good option for mixedic carcinoma
Model B
P value Hazard ratio 95% CI P value
0.455 0.984 0.566-1.711 0.954
0.001 1.472 1.059-2.047 0.028
<0.001 3.610 2.490-5.233 <0.001
0.017 0.424 0.167-1.074 0.070
0.047 – – –
0.285 – – –
– 2.222 1.259-3.920 0.006
r-2, L-H status Lauren classification and HER2 status.
des the combination factor of L-H status.
Figure 3 Kaplan–Meier curves of L-H status for overall survival in (A), TNM stage I/II and (B) TNM stage III/IV.
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analysis. We divided the gastric cancer patients according
to their L-H status to create four groups: Group A, HER2
negative and intestinal type; Group B, HER2 positive and
intestinal type; Group C, HER2 negative and diffuse type;
and Group D, HER2 positive and diffuse type. Group C had
the largest number of patients. Unsurprisingly, the patients
in Group A had the best prognosis, while those in Group D
had the worst. Although both intestinal type and L-H status
were independent prognostic factors in the multivariate
analysis, the -2log likelihood was smaller in the L-H status
model: the smaller the value of this statistic, the better
the model. Therefore, the L-H status was better than
the Lauren classification for predicting the prognosis.
In the multivariate analysis, age, TNM stage and L-H sta-
tus were all independent prognostic factors for gastric
adenocarcinoma patients. The L-H status could replenish
the TNM stage. Moreover, we found that L-H status was
an independent prognostic factor in stage I + II and stage
III + IV patients. Although the L-H status was not useful in
the mixed type, we recommend that all the gastric cancer
patients should be subjected to Lauren classification and
their HER2 status checked to determine their L-H status.
It is not only helpful to evaluate prognosis, but also is help-
ful to decide treatment. For HER2 positive metastasis gas-
tric cancer patients, trastuzumab is the standard treatment.
The limitations of the present study are: 1) its retro-
spective nature from a single-institution; 2) the fact that
the impact of various treatment-related outcomes could
not be fully evaluated; and 3) that progression free sur-
vival or disease free survival could not be fully analyzed.
External validation using other large databases or pro-
spective studies to evaluate the prognostic effect of L-H
status is required. The underlying mechanism of intes-
tinal type gastric cancer and relationship with high
HER2 expression requires further exploration.Conclusions
In this large sample size study, we found that HER2
positivity was not an independent prognostic factor in
the whole group of patients, but it was in the intestinal
type and stage I and II patients. The combination of the
Lauren classification and HER2 status (L-H status) was a
better prognostic factor than the Lauren classification
alone in the diffuse and intestinal type. We recommend
that all the gastric cancer patients should be subjected
to Lauren classification and their HER2 status checked
to determine their L-H status.
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